Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Morningside Healthcare Ltd., Unit C, Harcourt Way, Leicester, LE19 1WP, United Kingdom
Akizza 75 mcg / 20 mcg tablets.
| Pharmaceutical Form |
|---|
|
Film coated tablets. Round, white to off white, biconvex tablet debossed ‘A’ on one side and other side plain. |
Each film coated tablet contains 75 micrograms gestodene and 20 micrograms ethinylestradiol.
Excipient with known effect: contains 68.97 mg lactose (as lactose monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| 17 alpha-Ethinylestradiol |
Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy. |
|
| Gestodene |
|
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Tablet film-coating: Composition of Opadry white 03F58750 |
Tablets are packed in PVC/PVDC/Aluminium blisters inside a sealed tri-laminated pouch.
Pack sizes: 1 × 21 tablets; 3 × 21 tablets, 6 × 21 tablets, 13 × 21 tablets.
Not all pack sizes may be marketed.
Morningside Healthcare Ltd., Unit C, Harcourt Way, Leicester, LE19 1WP, United Kingdom
PL 20117/0252
24/08/2015
| Drug | Countries | |
|---|---|---|
| AKIZZA | United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
